MX9800967A - Compuestos quimicos. - Google Patents

Compuestos quimicos.

Info

Publication number
MX9800967A
MX9800967A MX9800967A MX9800967A MX9800967A MX 9800967 A MX9800967 A MX 9800967A MX 9800967 A MX9800967 A MX 9800967A MX 9800967 A MX9800967 A MX 9800967A MX 9800967 A MX9800967 A MX 9800967A
Authority
MX
Mexico
Prior art keywords
enzyme
cpb
prodrug
adept
humans
Prior art date
Application number
MX9800967A
Other languages
English (en)
Inventor
David Charles Blakey
David Huw Davies
Robert Ian Dowell
John Frederick Hennam
Peter Robert Marsham
Anthony Michael Slater
Laurent Francois And Hennequin
Original Assignee
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9516810.0A external-priority patent/GB9516810D0/en
Priority claimed from GBGB9611019.2A external-priority patent/GB9611019D0/en
Priority claimed from GBGB9612295.7A external-priority patent/GB9612295D0/en
Application filed by Zeneca Ltd filed Critical Zeneca Ltd
Publication of MX9800967A publication Critical patent/MX9800967A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Nanotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Sistemas de Terapia con Profármacos Enzimáticos Dirigidos a Anticuerpos (ADEPT) para usarse en el cáncer basados en enzimas carboxipeptidasas B (CPB) mutantes. Los conjugados enzimáticos para la ADEPT son sustancialmente no inmunogénicos en humanos que comprenden una porcion objetivo (por ejemplo un anticuerpo) capaz de unirse a un antígeno asociado con el tumor, la porcion objetivo está ligada a una forma mutante de una enzima CPB capaz de convertir un profármaco en un fármaco antineoplástico, en donde el profármaco no es convertible significativamente en un fármaco antineoplástico en humanos por enzimas no mutantes naturales. Un mutante enzimático preferido es una CPB pancreática humana que comprende un residuo de Lys o Arg en la posicion 253. En la especificacion se describen profármacos de mostaza adecuados.
MX9800967A 1995-08-16 1998-02-03 Compuestos quimicos. MX9800967A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9516810.0A GB9516810D0 (en) 1995-08-16 1995-08-16 Chemical compounds
GBGB9611019.2A GB9611019D0 (en) 1996-05-25 1996-05-25 Chemical compounds
GBGB9612295.7A GB9612295D0 (en) 1996-06-12 1996-06-12 Chemical compounds

Publications (1)

Publication Number Publication Date
MX9800967A true MX9800967A (es) 1998-11-29

Family

ID=27267862

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9800967A MX9800967A (es) 1995-08-16 1998-02-03 Compuestos quimicos.

Country Status (19)

Country Link
US (1) US6436691B1 (es)
EP (1) EP0844885A2 (es)
JP (1) JPH11511970A (es)
KR (1) KR19990036383A (es)
CN (1) CN1193278A (es)
AU (1) AU707689B2 (es)
BR (1) BR9610050A (es)
CA (1) CA2227040A1 (es)
CZ (1) CZ43098A3 (es)
GB (1) GB2317387B (es)
HU (1) HUP9900062A3 (es)
IL (1) IL123271A0 (es)
MX (1) MX9800967A (es)
NO (1) NO980630L (es)
NZ (1) NZ315713A (es)
PL (1) PL325017A1 (es)
SK (1) SK19498A3 (es)
TR (1) TR199800233T1 (es)
WO (1) WO1997007769A2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0844885A2 (en) 1995-08-16 1998-06-03 Zeneca Limited Chemical compounds
GB9703201D0 (en) * 1997-02-15 1997-04-02 Zeneca Ltd Chemical compounds
GB9709421D0 (en) * 1997-05-10 1997-07-02 Zeneca Ltd Chemical compounds
JP2002533072A (ja) * 1998-12-21 2002-10-08 イーライ・リリー・アンド・カンパニー β−リポトロピンおよび他のペプチドの組換え合成
BR0014527A (pt) * 1999-09-17 2002-06-18 Genzyme Transgenics Corp Proteìnas de fusão produzidas transgenicamente
WO2006035008A1 (de) * 2004-09-27 2006-04-06 Merck Biosciences Ag Rekombinante carboxypeptidase b
EP2318544A2 (en) * 2008-07-14 2011-05-11 The United States of America, as Represented by The Secretary, Department of Health and Human Services Method for predicting and detecting tumor metastasis
EP2350286B1 (en) * 2008-10-07 2016-07-20 The Regents of The University of California Recombinant nell protein production

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4364934A (en) 1979-12-04 1982-12-21 Ortho Pharmaceutical Corporation Monoclonal antibody to a human early thymocyte antigen and methods for preparing same
HU190129B (en) * 1983-07-11 1986-08-28 Reanal Finomvegyszergyar,Hu Process for the isolation of carboxypeptidase b enzyme from mammal pancreas
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
GB8809616D0 (en) 1988-04-22 1988-05-25 Cancer Res Campaign Tech Further improvements relating to drug delivery systems
US5632990A (en) 1988-04-22 1997-05-27 Cancer Research Campaign Tech. Ltd. Treatment for tumors comprising conjugated antibody A5B7 and a prodrug
AU648015B2 (en) 1989-01-23 1994-04-14 Akzo N.V. Site specific in-vivo activation of therapeutic drugs
US5433955A (en) 1989-01-23 1995-07-18 Akzo N.V. Site specific in vivo activation of therapeutic drugs
US5206161A (en) * 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
WO1993015208A1 (en) 1992-01-30 1993-08-05 Genzyme Limited Chiral synthesis with modified enzymes
US6187579B1 (en) * 1993-10-28 2001-02-13 Carlsberg A/S Customized proteases
GB9323429D0 (en) * 1993-11-12 1994-01-05 Wellcome Found Therapy
US5389537A (en) 1994-01-21 1995-02-14 Wisconsin Alumni Research Foundation Nuclease having altered specificity
MX9704575A (es) * 1994-12-23 1997-10-31 Zeneca Ltd Compuestos quimicos.
IL116696A (en) * 1995-01-25 1999-08-17 Bio Technology General Corp Production of enzymatically active recombinant carboxypeptidase b
US5837516A (en) * 1995-03-03 1998-11-17 Genentech, Inc. Subtilisin variants capable of cleaving substrates containing basic residues
EP0844885A2 (en) 1995-08-16 1998-06-03 Zeneca Limited Chemical compounds
US5985627A (en) * 1997-02-28 1999-11-16 Carlsberg Laboratory Modified carboxypeptidase

Also Published As

Publication number Publication date
GB2317387B (en) 1999-08-18
WO1997007769A3 (en) 1997-07-10
NO980630D0 (no) 1998-02-13
HUP9900062A3 (en) 1999-11-29
HUP9900062A2 (hu) 1999-04-28
WO1997007769A2 (en) 1997-03-06
PL325017A1 (en) 1998-07-06
NO980630L (no) 1998-04-07
AU707689B2 (en) 1999-07-15
US6436691B1 (en) 2002-08-20
KR19990036383A (ko) 1999-05-25
GB9726893D0 (en) 1998-02-18
CZ43098A3 (cs) 1998-05-13
CN1193278A (zh) 1998-09-16
AU6747696A (en) 1997-03-19
CA2227040A1 (en) 1997-03-06
SK19498A3 (en) 1998-09-09
NZ315713A (en) 1999-08-30
GB2317387A (en) 1998-03-25
BR9610050A (pt) 1999-10-13
EP0844885A2 (en) 1998-06-03
JPH11511970A (ja) 1999-10-19
IL123271A0 (en) 1998-09-24
TR199800233T1 (xx) 1998-06-22

Similar Documents

Publication Publication Date Title
AU1024699A (en) Use of a pentopyranosyl nucleoside for producing an electronic component, and conjugates of said pentopyranosyl nucleoside
TW272971B (es)
AU563356B2 (en) Conjugate of enzyme and antibody
NZ502745A (en) Use of superantigen conjugates for the directed cytolysis of target cells
NL300411I1 (nl) Werkwijze voor het met gebruikmaking van nieuwe cyanilerende reagentia
PL343205A1 (en) Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
AU6302694A (en) Lysosomal enzyme-cleavable antitumor drug conjugates
WO1991017773A3 (de) Neue protein-polykation-konjugate
AU4932199A (en) Cancer antigens based on tumor suppressor gene wt1 product
MY108864A (en) Peptide-carbohydrate conjugates generating t-cell immunity
EP0369566A3 (en) Bifunctional chimeric antibodies
MX9800967A (es) Compuestos quimicos.
AU4269796A (en) Chemical compounds
IL187595A0 (en) Antitumor antibodies, proteins, and uses thereof
NZ510154A (en) A tumour antigen protein and gene therefor, tumour antigen peptides and derivatives thereof in medicaments and prophylactics
AU6628386A (en) Ricin-antibody conjugates
AU6182994A (en) Bifunctional glycoproteins having a modified carbohydrate complement, and their use in tumor-selective therapy
AU638283B2 (en) Arylsulfatase
AU665546B2 (en) Conjugates for treating gastrointestinal tumours
AU2687992A (en) Sf-25 antibodies, especially chimeric antibodies, with specificity for the human tumor sf-25 antigen, methods for their production, and uses thereof